A Phase I/Ib Study Evaluating Single-Agent Inavolisib and Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

Disease Sites:

Head/Neck, Phase I

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Atezolizumab, Inavolisib

Principal Investigator(s):

Choe, Jennifer

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

01-12-2024

Trial Type:

Treatment

Protocol ID:

VICCHNP22118

National Clinical Trial ID:

NCT06496568

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available